EXHIBIT
31.1


CERTIFICATION OF


PRINCIPAL
EXECUTIVE AND FINANCIAL OFFICER


PURSUANT
TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002





I, Harris
A. Lichtenstein, Ph.D., the President, Chief Executive Officer and Director of
Omnimmune Holdings, Inc. (“Omnimmune”) certify that:
 
 1.
     I have reviewed this Quarterly Report on Form 10-Q of
Omnimmune for the period ended March 31, 2009;
 
 2.
     Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this
report;
 
 3.
     Based on my knowledge, the financial statements, and
other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows
of Omnimmune as of, and for, the periods presented in this report;
 
 4.
     Omnimmune’s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and
15d-15(f)) for Omnimmune and have:
 
 a.
     Designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to Omnimmune,
including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being
prepared;
 
 b.
     Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting
principles;
 
 c.
     Evaluated the effectiveness of Omnimmune’s disclosure
controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and
 
 d.
     Disclosed in this report any change
in  Omnimmune’s internal control over financial reporting that
occurred during Omnimune’s most recent fiscal quarter (Omnimmune’s fourth fiscal
quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, Omnimmune’s internal control over
financial reporting; and
 
 5.
     Omnimmune’s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over
financial reporting, to Omnimmune’s auditors and the audit committee of
Omnimmune’s board of directors (or persons performing the equivalent
functions):
 
 a.
     All significant deficiencies and material weaknesses in
the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect Omnimmune’s ability to record, process,
summarize and report financial information; and
 
 b.
     Any fraud, whether or not material, that involves
management or other employees who have a significant role in Omnimmune’s
internal control over financial reporting.


Date:
            May
      20, 2009Signature:
            /s/Harris A. Lichtenstein,
      Ph.D.Name: Harris
      A. Lichtenstein, Ph.D.Title: 
      President, Chief Executive Officer and Director
              Omnimmune
      Holdings, Inc.